Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Liabilities and Shareholders Equity (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Liabilities and Shareholders Equity data on record, last reported at $20.4 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 13.0% year-over-year to $20.4 million; the TTM value through Sep 2025 reached $79.9 million, down 32.32%, while the annual FY2024 figure was $16.9 million, 55.71% down from the prior year.
  • Liabilities and Shareholders Equity reached $20.4 million in Q3 2025 per MBRX's latest filing, down from $21.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $99.8 million in Q1 2021 and bottomed at $16.9 million in Q4 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $51.4 million, with a median of $47.1 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 291.74% in 2021, then tumbled 55.71% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $84.1 million in 2021, then plummeted by 31.71% to $57.4 million in 2022, then plummeted by 33.45% to $38.2 million in 2023, then crashed by 55.71% to $16.9 million in 2024, then rose by 20.25% to $20.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $20.4 million in Q3 2025, $21.6 million in Q2 2025, and $21.0 million in Q1 2025.